SILEN-C3, a Phase 2 Randomized Trial with Faldaprevir plus Pegylated Interferon α-2a and Ribavirin in Treatment-Naive Hepatitis C Virus Genotype 1-Infected Patients

Faldaprevir is an investigational hepatitis C virus (HCV) NS3/4A protease inhibitor which, when administered for 24 weeks in combination with pegylated interferon α-2a and ribavirin (PegIFN/RBV) in treatment-naive patients in a prior study (SILEN-C1; M. S. Sulkowski et al., Hepatology 57:2143–2154,...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Dieterich, Douglas, Asselah, Tarik, Guyader, Dominique, Berg, Thomas, Schuchmann, Marcus, Mauss, Stefan, Ratziu, Vlad, Ferenci, Peter, Larrey, Dominique, Maieron, Andreas, Stern, Jerry O., Ozan, Melek, Datsenko, Yakov, Böcher, Wulf Otto, Steinmann, Gerhard
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society for Microbiology 2014
Témata:
Antiviral Agents
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4068493/
https://ncbi.nlm.nih.gov/pubmed/24709256
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.02497-13
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky